Status:
RECRUITING
The Study of the Phenotype of Hereditary Xerocytosis
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Collaborating Sponsors:
Kremlin-Bicetre Hospital, Paris
Conditions:
Xerocytosis
Phenotype
Eligibility:
All Genders
10+ years
Phase:
NA
Brief Summary
Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to wa...
Eligibility Criteria
Inclusion
- Any patient diagnosed with hereditary xerocytosis according to the 2021 PNDS guidelines
- Covered by a social security plan
- Signature of the consent form for study participation by the patient, or for minors, by the parent(s)/legal representative(s).
Exclusion
- patients with other hemolysis reason
Key Trial Info
Start Date :
March 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06892171
Start Date
March 1 2025
End Date
March 1 2028
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Amiens
Amiens, France, 80090